# IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis

> **NCT06677710** · PHASE1 · SUSPENDED · sponsor: **Indapta Therapeutics, INC.** · enrollment: 34 (estimated)

## Conditions studied

- Multiple Sclerosis
- Primary Progressive Multiple Sclerosis (PPMS)
- Secondary Progressive Multiple Sclerosis (SPMS)
- Non-Active Secondary Progressive Multiple Sclerosis
- Non-Active SPMS
- Autoimmune Diseases of the Nervous System
- Nervous System Diseases
- Autoimmune Diseases
- Demyelinating Diseases
- Immune System Diseases
- Demyelinating Autoimmune Diseases, Central Nervous System (CNS)

## Interventions

- **DRUG:** IDP-023
- **DRUG:** Ocrelizumab
- **DRUG:** Interleukin-2
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **DRUG:** Mesna

## Key facts

- **NCT ID:** NCT06677710
- **Lead sponsor:** Indapta Therapeutics, INC.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2026-06-30
- **Primary completion:** 2026-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 34 (ESTIMATED)
- **Why stopped:** Business Reasons
- **Last updated:** 2025-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06677710

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06677710, "IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT06677710. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*